Organization | Istituti Ospitalieri di Cremona

Istituti Ospitalieri di Cremona Report issue

Academic/Hospital Phase 1 Phase 2 Phase 4

Founded: Cremona Italy

Organization Overview

First Clinical Trial

2011

NCT01681563

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2017

Timeline

NOW

Now

Alternative names

Istituti Ospedalieri di Cremona | Istituti Ospitalieri di Cremona | Istituti Ospitalieri di Cremona U.O.Complessa di Ematologia e CTMO

Active Ingredients

Drugs in Phase 4 Trials (1)

morphine (2 trials)

Drugs in Phase 2 Trials (5)

cyclophosphamide (cytoxan) (1 trial)

mesalamine (rowasa) (1 trial)

ofatumumab (arzerra) (1 trial)

olaparib (lynparza) (1 trial)

pentostatin (nipent) (1 trial)

Drugs in Phase 1 Trials (2)

eribulin (halaven) (1 trial)

everolimus (zortress) (1 trial)

Drugs in Other Trials (4)

bupivacaine (Exparel) (1 trial)

levobupivacaine (chirocaine) (1 trial)

polyethylene glycol (1 trial)

ropivacaine (naropin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Breast Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 2)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Triple Negative Breast Neoplasms (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 8
# of Trial APIs: 12